Adverse Drug Reaction not yet Described in the Scientific Literature (Case Report): Facial Hyperpigmentation Due to Use of Polymyxin B

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author TAKAHASHI, P. S. K. FMUSP-HC
DAL-PAZ, K. FMUSP-HC
BOSSI JR., F.
BARRETO, M. R.
SOUZA, A. B. FMUSP-HC
RIBEIRO, E. FMUSP-HC
FRANCA, G. G. FMUSP-HC
dc.date.issued 2012
dc.identifier.citation DRUG SAFETY, v.35, n.10, p.921-921, 2012
dc.identifier.issn 0114-5916
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/3153
dc.description.abstract Introduction: Polymyxin B has been used for treatment of surgical infectious complications, especially osteomyelitis caused by Acinelohacter baumannii1. Osteomyelitis is a condition which refers to an infection of the bone and it may be caused by different factors; these include underlying health conditions, injury to the bone or an infection that spread from the blood and causes damage to the bone2,3. Aim: To report an adverse reaction not described in the scientific literature with the medicine polymyxin B injection. Description: It was an observational study of the patient KMK, female, 70 years old, who has insulin dependent diabetes mellitus and labyrinthitis. She was admitted to the University Hospital of the University of São Paulo (HU/USP) for repair the distal left femur fracture and underwent reoperations due to various infectious complications in the surgical site. Thus, it was prescribed polymyxin B at a dosage of 350 000IU, intravenous 12/I2h (started on the 17th February 2012) for Acinetobacler baumannii revealed in bone fragment (11th February 2012). Results: After 7 days of treatment (24th February 2012) with polymyxin B, the patient presented with dermatitis, especially in the face. Further, in the patient's medical report it was described as hyperpigmentation from 28th February 2012. To treat this condition, it was prescribed betamethasone cream twice a day and the replaced by hydrocortisone cream twice a day. The diagnostic hypothesis of hyperpigmentation is related to the use of polymyxin B. There was no interruption during the hospitalization period. On March 30th 2012, she was discharged from the hospital with prescription of polymyxin B and teicoplanin. The patient remains with hyperpigmentation on her face, with injury, and she has been assisted at our ambulatory. Antibiotic therapy is planned to last more six months. Conclusions: We can infer that it was the first time that such adverse drug reaction was described. It is very important to alert the scientific community to the possibility of hyperpigmentation caused the use of polymyxin B. Further studies are needed to elucidate the mechanism that triggers this process of hyperpigmentation as well as the adoption of measures for the detection, control and treatment.
dc.language.iso eng
dc.publisher ADIS INT LTD
dc.relation.ispartof Drug Safety
dc.rights restrictedAccess
dc.title Adverse Drug Reaction not yet Described in the Scientific Literature (Case Report): Facial Hyperpigmentation Due to Use of Polymyxin B
dc.type conferenceObject
dc.rights.holder Copyright ADIS INT LTD
dc.description.conferencedate OCT 30-NOV 02, 2012
dc.description.conferencelocal Cancun, MEXICO
dc.description.conferencename 12th Annual Meeting of the International-Society-of-Pharmacovigilance (ISoP) on New Landscapes for Pharmacovigilance
dc.type.category meeting abstract
dc.type.version publishedVersion
hcfmusp.author TAKAHASHI, P. S. K.:HU:
hcfmusp.author DAL-PAZ, K.:HC:IOT
hcfmusp.author SOUZA, A. B.:HU:SVFARMH-62
hcfmusp.author RIBEIRO, E.:HC:INCOR
hcfmusp.author FRANCA, G. G.:HU:SVFARM-62
hcfmusp.author.external · BOSSI JR., F.:Univ Sao Paulo, Fac Pharm, Sao Paulo, Brazil
· BARRETO, M. R.:Univ Sao Paulo, Fac Pharm, Sao Paulo, Brazil
hcfmusp.origem.id WOS:000309083600099
hcfmusp.publisher.city AUCKLAND
hcfmusp.publisher.country NEW ZEALAND
hcfmusp.relation.reference · Carvalho Vladimir Cordeiro de, 2012, Braz J Infect Dis, V16, P63
· Elias LS, 2010, J ANTIMICROB CHEMOTH, V65, P2231, DOI 10.1093/jac/dkq285
· Knueppel RC, 2007, CLIN INFECT DIS, V45, P136, DOI 10.1086/520486
dc.description.index MEDLINE
hcfmusp.citation.wos 0
hcfmusp.affiliation.country Brasil


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics